Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602668 | 0.82 | LPL (0.53) | LPLLIPGENPP2NLRP3KDM4E | |
| SCHEMBL15150688 | 0.81 | ENPP2 (0.46) | LPLLIPGENPP2NLRP3KDM4E | |
| SCHEMBL7268637 | 0.80 | LPL (0.56) | LPLLIPGENPP2ALDH1A1MGLL | |
| SCHEMBL8626033 | 0.80 | NLRP3 (0.40) | LPLLIPGENPP2NLRP3KDM4E | |
| SCHEMBL3785229 | 0.79 | LPL (0.39) | LPLLIPGNLRP3MGLLTRPV1 | |
| SCHEMBL3191409 | 0.79 | ENPP2 (0.48) | LPLLIPGENPP2NLRP3KDM4E | |
| SCHEMBL3363357 | 0.79 | MAPT (0.50) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL69849 | 0.78 | ENPP2 (0.50) | LPLLIPGENPP2NLRP3KDM4E | |
| SCHEMBL2364427 | 0.78 | NLRP3 (0.41) | LPLLIPGENPP2NLRP3KDM4E | |
| SCHEMBL21369168 | 0.77 | ENPP2 (0.45) | LPLLIPGENPP2NLRP3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | LPL 3816/4885LIPG 3010/4885ENPP2 1920/4885 |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | LPL 1796/4885LIPG 499/4885ENPP2 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.